Replies to post #656056 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

I will guarantee that UK reimbursements will not be approved by Dec 2024

Why not? DCVax-L could be recommended by NICE at the same time it received its licence from MHRA.

First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK

17 October 2023

NICE has recommended glofitamab as a new treatment option for adults with relapsed or refractory diffuse large B cell lymphoma after 2 or more systemic treatments in final guidance published today (17 October 2023).

Today’s recommendation for its use in the NHS coincides with glofitamab receiving its licence from the Medicines and Healthcare Products Regulatory Agency (MHRA).

https://www.nice.org.uk/news/article/first-treatment-to-be-recommended-by-nice-at-the-same-time-it-is-approved-for-advanced-lymphoma-in-the-uk

NHS England will use the Cancer Drugs Fund (CDF) to provide fast-tracked access to the treatment ahead of its future funding from routine commissioning.

https://www.england.nhs.uk/2023/10/new-treatment-that-could-prove-curative-for-blood-cancer-patients-to-be-offered-by-the-nhs/